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Dysregulation of Human Phase I Enzymes in
AP AP Overdose Subjects with Low AL T Levels
Aaron Woodall
Background: Acetaminophen (APAP) is a common analgesic that can cause liver injury and death
in high doses. Changes in gene expression following APAP overdose may be more sensitive
indicators of liver injtrry than the current clinical indicator, alanine aminotransferase (ALT). The aim
of this study was to examine gene expression of Phase I enzymes in pediatric AP AP overdose
patients with low ALT levels (<75 lUlL), in order to understand the mechanism of APAP toxicity.
Methods: Blood samples were collected from control patients (no AP AP exposure; N=5) and APAP
overdose patients {N=S). Using the P AXgene system, RNA was extracted from the blood samples
and eDNA was synthesized. Quantitative polymerase chain reaction (qPCR) was performed and
samples were profiled with an array containing 84 Phase I Enzyme drug metabolism genes.
Results: The low ALT pediatric APAP overdose patients had higher (median [range]) ALT levels
(35 [25,48] lUlL) compared to controls (16 [7, 20] IUIL). Three genes had significant
downregulation that was later confirmed: GZMB (-2.86 fold, p<O.O I), ALDH6A 1 (-2.13 fold,
p<O.Ol), and CYP4F12 (-4.04 fold, p<O.OS). Pathway analysis for the three genes pointed to
signaling pathways connected to apoptosis, metabolism of valine and leucine (involved in the
immune response), and hydroxylation of leukotriene B4 (involved in inflammation).
Conclusion: Dysregulation of Phase I Enzyme drug metabolism pathways has relevance for
understanding mechanisms of cell injury in APAP toxicity. Pathway analysis points to the potential
for a weakened immune response associated with AP AP overdose.

INTRODUCTION
Acetaminophen (APAP) is a mild analgesic
found in many over-the-counter drugs. Taken in
normal doses, it is generally regarded as safe
and non-toxic, though liver injwy is common.
AP AP overdose is the leading cause of acute
liver failure in the United States [6].
Acetaminophen overdose is a common
problem in the United States. A 2015 study
(conducted from 2006-20 I0) showed that in the
United States alone, 82,362 people visited the
emergency room every year for APAP
overdose. Every year, there were roughly 494
deaths caused by acetaminophen toxicity [1].

APAP toxicity does not have a clearly
defined limit. Tylenol, the largest and most
well-known distributer of APAP, recommends a
maximum daily dosage of 3,000 mg for adults.
For children, this amount greatly varies by
weigh l and age [ I0]. Nonetheless, the
acetaminophen toxicity limit varies from person
to person.
The clinical biomarker for APAP overdose is
alanine aminotransferase (ALT). Raised ALT
levels indicate liver injwy, but this is not
specific to acetaminophen (6]. APAP adducts
arc fonncd in the metabolism of acetaminophen.
AP AP is metabolized by Phase I enzymes in the
cytochrome P450 family (namely CYP2El) into
N-acetyl-p-benzoquinone imine (NAPQI), a
toxic reactive intermediate metabolite. When
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NAPQI binds to the cysteine group on a protein,
APAP adducts are formed [7]. In a therapeutic
dose of AP AP, this material is detoxified by
glutathione and is excreted. Thus, these adducts
are only present in patients who have exceeded
the normal dosage of APAP and present liver
il\iury [6, 7].
The lab previously studied APAP overdose
in patients with severe liver injury, defined as
having ALT levels >75 TU/L. The five high
ALT blood samples were run in qPCR against
five control samples, and three genes were
identified as being dowmegulated (using a 2fold and p<0.05 cut-oft): ALDHlAl,
CYP27Al, and GZMB. The downregulation of
all three genes was confirmed by individual
analysis.
This study functioned as a follow-up to the
high ALT experiment and a conclusion to the
lab's PA.Xgene APAP overdose project. In this
study, we investigated gene dysregulation of
APAP overdose patients who exhibited mild
liver injury, or low ALT levels, to better
understand acetaminophen's pathway to cell
injury.

METHODS
Sample Collection
The study focused on pediatric AP AP
overdose patients with low ALT levels from
Arkansas Children's Hospital. Patients who
were in the hospital due to AP AP overdose and
presented a mild liver injury, defined as ALT
levels <75 IU/L, were identified and selected for
the study. Blood samples were collected by
nurses who were aware of the study and
delivered to the lab for research. ALT levels and
AP AP adduct levels were measured for each
sample. Blood samples were stored in PAXgene
Blood RNA tubes (PreAnalytiX, GmbH,
Switzerland). This study included five AP AP
overdose samples (low ALT levels) and five
control samples (randomly identified and

selected with no AP AP influence in the last two
weeks).

RNA Isolation and eDNA Synthesis
The PA.Xgcnc Blood miRNA system was
used for the purification of total RNA from
peripheral blood collected in PA.Xgene Blood
RNA Tubes. PAXgene-extracted RNA was
quantified using spectrophotometer
(NanoDrop™ 1000, Thenno Fisher Scientific,
Wilmington, DE). eDNA synthesis was
performed using the RT2 First Strand kit
(Qiagen).

Phase I PCR Array
For target gene expression analysis, Phase I
Enzymes RP Profiler™ PCR Array (PAHS~
068Z), which contains 84 genes involved in
Phase I drug metabolism, were used with the
SYBR®Green system (Qiagen). The ABI
QuantStudio 6 Flex Real Time PCR cycler
(Applied Biosystems) was used to perfonn
quantitative real-time PCR (qPCR). All
experiments were performed in DNase/RNase
free conditions and n01malized to GAPDH. The
analysis was performed by Threshold Cycle
Method and the fold change obtained by the
delta CT method. Qiagen's qPCR analysis tool,
available on
http://pcrdataanalysis.sabiosciences.com/pcr/arr
ayanalysis.php, was used for analysis. The
Volcano plot considered genes that had 2:2 fold
change and a p-value <0.05 in the t-test.
eDNA Expression Analysis
Quantitative real time PCR (qPCR) was
performed for all samples in triplicate on
QuantStudioTM 6 Flex Real-Time PCR System
(TbermoFisher Scientific, Carlsbad, CA). qRTPCR quantification of eDNA expression was
performed using assays and accompanying
reagents from Qiagen eDNA analyses were
performed using Primer Assays for aldehyde
dehydrogenase 6 family, member Al
(ALDH6A l; PPH16308B), Cytochrome P450
family 4, subfamily F, polypeptide 12
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(CYP4Fl2, PPH01237F), Granzyme B (GZMB;
PPH02594A), and Beta Actin ( ACTB;
PPH00073G). For each primer assay, negative
controls were run with water and eDNA
samples. For no template controls (NTC) a
master mix with no eDNA was used. Data
normalization was performed with ACTB.
Relative quantitation was calculated using the
delta CT method. Pathway analysis was
performed for each of the identified genes using
The Human Gene Database available at
http://www.genecards.org/.

RESULTS
The ALT levels and AP AP adduct levels in
the APA overdose low ALT group were
significantly higher than those in the control
group, both with p-values <0.01 (Figure 1).
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The qpCR array, analyzed with the Qiagen
web portal qPCR analysis tool, identified three
genes as dysregulated, defined as having a fold
change =:::2 and a p-value <0.05. They were
identified on a volcano plot that plots -log( fold
change) against -log(p-value) for each of the 84
genes profiled in the qPCR array (Figure
2).ALDH6Al , GZMB, and CYP4F 12 were all
identified as downrcgulated in the low ALT
APAP overdose samples. The individual qPCR
validation assays confirmed the downrcgulation
of all three genes (Figure 3).
GeneCards' reported pathway analysis shows
that ALDH6Al is involved in metabolic
pathways in the degradation of valine, leucine,
and isoleucine [2]~ GZMB is involved in the
Granzyme-B pathway of the immune response,
specifically in apoptosis [4]; and CYP4F l 2
catalyzes leukotriene B4 omega-hydroxylation
[3].

7
10

16
18

0.0001
0.0009
0.0038
0.008

14
13

0.0032

48
25
35

33

0.4403
0.6983
0.6663
0.7767

35
35.2

0.6454

Figure 1: Sample data for control and APAP overdose (low ALT) groups. The test group had higher
ALT levels (p=0.0017) and significantly higher APAP adduct levels (p=0.0030).
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Figure 2: Volcano plot that identifies dysregulated genes. Plots -log( fold change) against -log(pvalue). Three genes were identified as downregulated: GZ:MB, ALDH6Al, and CYP4Fl2.

Gene
ALDH6Al
GZMB
CYP4Fl2

Initial
Fold
Change
-2.1281
-2.8555
-4.0393

Initial
p-value
0.00588
0.00201
0.01208

Validation
Fold
Change
-1.5945
-1.3148
-6.6555

Figure 3: Fold change values for dysregulated genes. Initial fold change values and p-values
identified with volcano plot from initial qPCR array. Validation fold change values identified using
delta CT method from individual validation qPCR assays.

DISCUSSION
Based on this study, ALDH6Al, GZMB, and
CYP4F12 are all downregulated in pediatric
AP AP overdose patients with mild liver injury
from Arkansas Children's Hospital. Further
research that expands the PAXgcne database is

needed to confitm these results, as the sample
size was limited to the patients available in the
hospital.
The most interesting results come from the
pathway analysis of the three genes, and the
related damage that APAP overdose may cause.
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ALDH6A 1 is involved in the metabolism of
three branched chain amino acids (BCAAs) [2].
Valine, leucine, and isoleucine are the three
essential BCAAs that facilitate glucose uptake
in the liver and aid in protein synthesis.
Research suggests that impairing the
degradation of BCAAs leads to their buildup
and can produce toxic materials. BCAAs are
also essential for the growth of lymphocytes and
cytotoxic T cell activity, meaning that they play
an important role in the immune response [9).
With the downregulation of an enzyme that
metabolizes these amino acids, their activity and
role in the immune response would potentially
be weakened. Further research to find a link
between AP AP overdose and the
downregulation of ALDH6Al is needed, but
this study may suggest a pathway of liver injury
through BCAAs, as well as a weaker immune
response as a result.
GZMB is involved in the immune response
[4]. It is released by natural killer ceUs and
cytotoxic T cells to induce target cell apoptosis.
GZMB also plays a role in chronic
inflammation and wound healing [5]. A
downregulation of this gene may cause a
weakened immune response. GZMB was also
found to be downregulated in a previous study,
mentioned above, of this lab with AP AP
overdose patients who presented severe liver
injury (ALT levels >75 lUlL). A comprehensive
study will be published in the near future.
Further research that focuses specifically on the
role of GZMB in APAP metabolism is needed
to confirm these results and establish a
connection between the gene dysregulation and
potential cell injuries.
CYP4F12 is involved in the hydroxylation of
leukotriene B4 (LTB4) [3]. LTB4 is an epoxide
that is an inflammatory mediator [8].
Inflammation is also an important part of the
immune response. This suggests that the
downregulation ofCYP4F12 may affect the
effectiveness of inflammation and the overall
immune response. Further research into

differences of inflammatory responses in
pediatric APAP overdose patients would be
interesting.
The downregulated genes point to a potential
weakening of the immune response related to
APAP overdose, especially in the liver. To
confitm these suspicions, further research would
need to be done to confirm the initial
downregulation of the Phase I enzymes.
Extensive experimentation would need to be
conducted with APAP overdose patients that
tested their immune response. Though not
conclusive, this study points to a potential for
cell injury associated with APAP overdose
outside of the known liver damage. It also gives
insight into potential biomarkers through the
affected enzymes.

ARKANSAS CHILDREN'S RESEARCH
INSTITUTE
My summer interning at Arkansas Children's
Research Institute was an educational and
highly beneficial experience. Working in Dr.
Laura James' lab under Dr. Prit Gill, I learned
valuable laboratory skills and improved upon
my professional communication. As part of the
Summer Science Program, I was also able to
hear from and shadow medical professionals in
various departments of the hospital. These
experiences expanded my knowledge and
helped to prepare me to enter a physician
assistant program in the coming year, and to one
day be a health care provider myself.
While working in the laboratory, I learned
new lab techniques, including plating samples in
preparation for qPCR, operating the PCR cycler,
and data analysis. In addition to my project, I
had the opportunity to assist in other projects
that the lab was working on. For a related study,
researching the effects of acetaminophen
exposure on mouse Leydig cells, I learned how
to perform cell culture. This involved splitting
the cells, preparing acetaminophen doses,
treating the cells with the drug, and extracting
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RNA to perform qPCR similar to that done with
the PAXgene blood samples.
Working closely with Dr. Gill improved my
professional communication skills. I learned
how to contribute to meetings by staying up-todate on reading articles and learning more about
the subject, which was all relatively new to me.
I also spent a lot of my time on my own, so I
learned to work independently in a lab setting,
another new experience for me. My internship
allowed me to network and to develop a
professional relationship with my mentors that
will greatly benefit me in the future.
Aside from researching, the Arkansas
Children's Research Institute Summer Science
Program provided twenty-two other students
and me with opportunities to meet medical
professionals. Most of us were in college with
aspirations to attend a medical graduate program
and practice in the health profession. We
enjoyed a lecture series twice a week during the
eight-week program where we heard from
different professionals, including a
neonatologist, a geneticist, a pediatric
psychologist, an emergency medicine physician,
a neurosurgeon, and others from diverse
backgrounds and areas. This introduced me to
areas of medicine that I knew close to nothing
about, and helped me continue to decide what
area of medicine I wanted to enter.
Along with the lectures, the shadowing
opportunities were immensely beneficial and
essential to the overall experience. One of the
most interesting experiences I had was
shadowing a medical ethicist during his
pediatric intensive care unit rounds. We
discussed ethical questions that arose during
hospital care, and how he worked with the
physicians to ensure that patients were cared for
with regard to the best medical practices as well
as the patient's wishes. It opened my eyes to
ethical dilemmas I had never considered. I also
had the chance to shadow in the general
pediatric surgery unit and the emergency
department. Both of these were areas I had

never experienced from the side of the provider.
I became very interested in both of these highstakes fields and excited at the possibility of one
day working in one of them.
However, the most important shadowing
experience I had was with the physician
assistant team in cardiovascular surgery.
Shadowing with the physician assistants
confirmed my desire to apply for physician
assistant school and enter the field. I had the
opportunity to sit in a pre-operation consultation
day, two different open-heart surgeries, and
post-operation intensive care rounds. The
physician assistants worked with their patients
throughout their entire treatment and I had the
chance to see all of the aspects. This experience
inspired me and helped me be accepted into the
physician assistant program.
Overall, my summer internship at Arkansas
Children's Research Institute was highly
beneficial. I would strongly suggest that those
who wish to enter to medical field apply for
similar programs or experiences, as they
expanded my knowledge and gave me
invaluable opportunities. Because ofthe
opportunity to independently research and my
time spent shadowing and networking with
medical professionals, I feel better prepared to
enter into a career in the health care field.
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*In accordance with Dr. Prit Gill and his pending
manuscript, "Granzyme B and miR-738a
interaction in acetaminophen toxicity," which is
awaiting publication.

